The KRT2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, engineered to disrupt the KRT2 gene. This product provides a heterogeneous pool of cells with targeted gene disruption, enabling the study of loss-of-function effects without clonal isolation. The polyclonal format captures the diversity of editing outcomes across the cell population, offering a robust model for investigating intermediate filament dynamics and keratin biology in a cancer cell context.
The host HeLa cell line is an HPV18-positive cervical adenocarcinoma model originating from Henrietta Lacks, widely employed in cancer research due to its robust growth and well-characterized background. In this line, the tumor suppressor p53 is inhibited by the HPV E6 oncoprotein, contributing to genomic instability and unchecked proliferation. HeLa cells serve as a versatile platform for studying cancer cell biology, including signal transduction, cytoskeletal organization, and drug response, making them a relevant host for keratin gene knockout studies despite their non-epidermal origin.
KRT2 encodes a type II keratin intermediate filament protein that provides mechanical integrity to suprabasal keratinocytes in the epidermis. Its expression is transcriptionally regulated by p63, CCAAT/enhancer-binding proteins (C/EBPs), activator protein 1 (AP-1), and Notch signaling. KRT2 interacts with keratin 10 (KRT10), desmoplakin (DSP), plakoglobin (JUP), and filaggrin (FLG) to assemble the intermediate filament network and recruit desmosomal proteins. Downstream, KRT2 promotes terminal epidermal differentiation, including involucrin (IVL), loricrin (LOR), and keratins KRT5, KRT14, and KRT1. Disruption of KRT2 compromises the keratin network, impairing mechanical resilience and barrier function, as seen in ichthyosis bullosa of Siemens.
In HeLa cells, KRT2 knockout allows study of intermediate filament network perturbations in a cancer cell background. Although not of epidermal origin, HeLa cells express keratins and associated proteins, enabling investigation of cytoskeletal dynamics, cell adhesion, and migration. The polyclonal knockout population facilitates assessment of population-level responses to keratin disruption, including viability, desmosome integrity, and invasive potential. This system also supports screening for modulators of keratin expression or filaggrin processing, linking keratin biology to cancer mechanics.
Typical research applications include CRISPR validation by genomic DNA PCR and sequencing, protein analysis by western blotting and immunofluorescence, and functional assays of migration, invasion, and viability. The polyclonal KRT2 knockout HeLa cells are suited for intermediate filament dynamics studies, cancer cell biomechanics, and high-throughput screening for compounds that modulate keratin assembly. For further information, please contact Ascent Research.
